Published in J Am Coll Cardiol on June 01, 1999
Effectiveness of ECP Therapy in Stable Angina Pectoris Patients | NCT04873687
Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol (2010) 1.69
Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study. Circulation (2010) 1.60
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag (2010) 1.16
Exercise-induced Signals for Vascular Endothelial Adaptations: Implications for Cardiovascular Disease. Curr Cardiovasc Risk Rep (2012) 0.95
Effects of enhanced external counterpulsation on arterial stiffness and myocardial oxygen demand in patients with chronic angina pectoris. Am J Cardiol (2011) 0.94
Alternative treatments for angina. Heart (2007) 0.90
A novel external counterpulsation system for coronary artery disease and heart failure: pilot studies and initial clinical experiences. J Artif Organs (2010) 0.88
Cause or effect of arteriogenesis: compositional alterations of microparticles from CAD patients undergoing external counterpulsation therapy. PLoS One (2012) 0.86
Management standards for stable coronary artery disease in India. Indian Heart J (2016) 0.86
Effect of enhanced external counterpulsation on inflammatory cytokines and adhesion molecules in patients with angina pectoris and angiographic coronary artery disease. Am J Cardiol (2007) 0.85
Enhanced external counterpulsation for ischemic heart disease: a look behind the curtain. Exerc Sport Sci Rev (2012) 0.85
Self management training in refractory angina. BMJ (2008) 0.81
Enhanced external counterpulsation in ischemic heart disease and congestive heart failure. CMAJ (2004) 0.81
Cardiac Syndrome X: update 2014. Cardiol Clin (2014) 0.81
Collaterals: Implications in cerebral ischemic diseases and therapeutic interventions. Brain Res (2015) 0.81
One year follow-up of patients with refractory angina pectoris treated with enhanced external counterpulsation. BMC Cardiovasc Disord (2006) 0.80
A historical perspective towards a non-invasive treatment for patients with atherosclerosis. Neth Heart J (2009) 0.79
Effect of enhanced external counterpulsation on circulating CD34+ progenitor cell subsets. Int J Cardiol (2010) 0.79
Transmyocardial revascularization devices: technology update. Med Devices (Auckl) (2014) 0.78
Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis. Ont Health Technol Assess Ser (2006) 0.78
Effect of enhanced external counterpulsation treatment on renal function in cardiac patients. BMC Nephrol (2013) 0.78
Passive tobacco exposure may impair symptomatic improvement in patients with chronic angina undergoing enhanced external counterpulsation. BMC Cardiovasc Disord (2008) 0.78
Enhanced external counter pulsation in treatment of refractory angina pectoris: two year outcome and baseline factors associated with treatment failure. BMC Cardiovasc Disord (2008) 0.78
Effects of enhanced external counterpulsation on anginal symptoms and improvements in objective measures of myocardial ischaemia. Cardiovasc J Afr (2007) 0.77
Effect of Enhanced External Counterpulsation (EECP) on Exercise Time Duration and Functional Capacity in Patients with Refractory Angina Pectoris. J Tehran Heart Cent (2014) 0.77
Enhanced external counterpulsation for refractory angina pectoris. Heart (2003) 0.77
Enhanced external counterpulsation improves endothelial function and exercise capacity in patients with ischaemic left ventricular dysfunction. Clin Exp Pharmacol Physiol (2014) 0.77
EECP-enhanced external counterpulsation. J Am Coll Cardiol (1999) 0.77
The role of enhanced external counter pulsation therapy in clinical practice. Clin Med Res (2013) 0.77
Cardiac shockwave therapy in patients with chronic refractory angina pectoris. Neth Heart J (2016) 0.76
Chinese consensus statement on the evaluation and intervention of collateral circulation for ischemic stroke. CNS Neurosci Ther (2014) 0.76
Therapeutic approaches in the stimulation of the coronary collateral circulation. Curr Cardiol Rev (2014) 0.75
Reduced peripheral vascular reactivity in refractory angina pectoris: Effect of enhanced external counterpulsation. J Geriatr Cardiol (2011) 0.75
Efficacy of Enhanced External Counterpulsation in Patients With Chronic Refractory Angina on Canadian Cardiovascular Society (CCS) Angina Class: An Updated Meta-Analysis. Medicine (Baltimore) (2015) 0.75
The Effects of Enhanced External Counterpulsation on Cardiac Electrophysiologic Properties of Patients with Ischemic Heart Disease and Refractory Angina at Function Class II-III. J Cardiovasc Thorac Res (2011) 0.75
The role of enhanced external counterpulsation in the treatment of angina and heart failure. Can J Cardiol (2007) 0.75
A retrospective pilot study of correlation of cerebral augmentation effects of external counterpulsation with functional outcome after acute ischaemic stroke. BMJ Open (2015) 0.75
Does Enhanced External Counterpulsation (EECP) Significantly Affect Myocardial Perfusion?: A Systematic Review & Meta-Analysis. PLoS One (2016) 0.75
External Counterpulsation Reduces Beat-to-Beat Blood Pressure Variability When Augmenting Blood Pressure and Cerebral Blood Flow in Ischemic Stroke. J Clin Neurol (2016) 0.75
Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease. Eur Heart J Qual Care Clin Outcomes (2016) 0.75
Toxic shock syndrome: A rare complication to enhanced external counterpulsation. Can J Cardiol (2010) 0.75
Enhanced external counterpulsation reduces indices of central blood pressure and myocardial oxygen demand in patients with left ventricular dysfunction. Clin Exp Pharmacol Physiol (2015) 0.75
The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina. Glob Cardiol Sci Pract (2014) 0.75
Treatment of refractory angina. Ochsner J (2009) 0.75
Feasibility and Safety of Using External Counterpulsation to Augment Cerebral Blood Flow in Acute Ischemic Stroke-The Counterpulsation to Upgrade Forward Flow in Stroke (CUFFS) Trial. J Stroke Cerebrovasc Dis (2015) 0.75
Effect of Enhanced External Counter Pulsation Treatment on Aortic Blood Pressure, Arterial Stiffness and Ejection Fraction in Patients with Coronary Artery Disease. J Clin Diagn Res (2016) 0.75
Anti-ischemic effect of enhanced external counterpulsation: where's the beef? J Am Coll Cardiol (2000) 0.75
Novel molecular targets for coronary angiogenesis and ischemic heart disease. Coron Artery Dis (2017) 0.75
Novel external counterpulsation system, compact counterpulsation, was effective to treat severe ischemic heart failure: a case report. J Artif Organs (2014) 0.75
Evidence of clinical efficacy of counterpulsation therapy methods. Heart Fail Rev (2015) 0.75
Effect of enhanced extracorporeal counterpulsation in patients with non-arteritic anterior ischaemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol (2014) 0.75
Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem (1986) 4.80
Characterization of the human p53 gene. Mol Cell Biol (1986) 4.33
Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J (1987) 3.81
Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J (1988) 3.81
Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int (2007) 3.17
Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J (1984) 2.45
Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J (1982) 2.29
Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med (2001) 2.26
The 53,000-dalton cellular protein and its role in transformation. Int Rev Exp Pathol (1983) 2.19
Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology (1990) 2.17
Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med (2000) 2.14
Echocardiography in patients with suspected endocarditis: a cost-effectiveness analysis. Am J Med (1999) 2.13
Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature (1991) 2.09
Should the electrocardiogram be used to guide therapy for patients with left bundle-branch block and suspected myocardial infarction? JAMA (1999) 2.02
The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J (2001) 2.01
Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford) (2004) 2.01
The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia. Am J Cardiol (1987) 1.94
Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem (1986) 1.91
Cellular proteins reactive with monoclonal antibodies directed against simian virus 40 T-antigen. J Virol (1982) 1.90
External quality assessment in the examination of blood films for malarial parasites within Ontario, Canada. Arch Pathol Lab Med (2000) 1.89
Effect of autonomic nervous system dysfunction on the circadian pattern of myocardial ischemia in diabetes mellitus. J Am Coll Cardiol (1994) 1.86
Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J (1989) 1.84
Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol (1994) 1.84
Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas. J Gen Virol (1987) 1.78
Myocardial perfusion imaging with 99mTc tetrofosmin. Comparison to 201Tl imaging and coronary angiography in a phase III multicenter trial. Tetrofosmin International Trial Study Group. Circulation (1995) 1.71
Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology (1995) 1.65
Is proximal demarcation of ulcerative colitis determined by the territory of the inferior mesenteric artery? Lancet (1995) 1.58
Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation (1991) 1.57
Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr (1994) 1.57
Renal artery stenosis and focal segmental glomerulosclerosis in the contralateral kidney. Nephrol Dial Transplant (1998) 1.53
Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-alpha by macrophages. J Immunol (2000) 1.49
Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation (1992) 1.45
Adenosine inhibits norepinephrine release in the postischemic rat heart: the mechanism of neuronal stunning. Cardiovasc Res (2001) 1.45
Stenting for in-stent restenosis: A long-term clinical follow-up. Catheter Cardiovasc Interv (1999) 1.43
Proficiency testing of hemoglobinopathy techniques in Ontario laboratories. Am J Clin Pathol (1997) 1.42
False-positive PCR results linked to administration of seasonal influenza vaccine. J Med Microbiol (2011) 1.41
Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol (1988) 1.41
Preoperative dipyridamole thallium imaging and ambulatory electrocardiographic monitoring as a predictor of perioperative cardiac events and long-term outcome. Anesthesiology (1995) 1.40
HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene (1993) 1.40
Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care (2001) 1.37
Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol (1992) 1.35
Differential host range of viruses of feline leukemia-sarcoma complex. Virology (1975) 1.35
Role of behavioral and psychological factors in mental stress-induced silent left ventricular dysfunction in coronary artery disease. J Am Coll Cardiol (1993) 1.33
Evidence for linkage of a tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD). Mol Psychiatry (2000) 1.30
Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Bioessays (1995) 1.26
Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. Oncogene (1991) 1.26
Characterization of the human p53 gene promoter. Mol Cell Biol (1989) 1.25
Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the hormone-dependent transformation of primary mouse cells. Proc Natl Acad Sci U S A (1988) 1.24
p53 in chronic myelogenous leukemia. Study of mechanisms of differential expression. J Exp Med (1988) 1.24
Diabetic cardiomyopathy. Am Heart J (1989) 1.22
Functional studies of E7 proteins from different HPV types. Oncogene (1994) 1.22
Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med (1988) 1.21
Destabilizing effects of mental stress on ventricular arrhythmias in patients with implantable cardioverter-defibrillators. Circulation (2000) 1.21
Uniform nomenclature for monoclonal antibodies directed against virus-coded proteins of simian virus 40 and polyoma virus. J Virol (1982) 1.18
Co-transformation by human papillomavirus types 6 and 11. J Gen Virol (1990) 1.17
Purification and partial amino acid sequence analysis of the cellular tumour antigen, p53, from mouse SV40-transformed cells. EMBO J (1983) 1.16
Iron deficiency anaemia in sickle cell disorders in India. Indian J Med Res (2008) 1.15
Mutations of the human papillomavirus type 16 E7 gene that affect transformation, transactivation and phosphorylation by the E7 protein. J Gen Virol (1990) 1.11
Permanent expression of p53 in FR 3T3 rat cells but cell cycle-dependent association with large-T antigen in simian virus 40 transformants. EMBO J (1985) 1.10
Comparison of infrared ear thermometer derived and equilibrated rectal temperatures in estimating pulmonary artery temperatures. Crit Care Med (1996) 1.09
Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol (1995) 1.08
Acute myocardial infarction and diabetes mellitus. Cardiovasc Res (1993) 1.08
An evaluation of peripheral blood eosinophil/basophil progenitors following nasal allergen challenge in patients with allergic rhinitis. Clin Exp Allergy (2005) 1.08
Comparing sugammadex and neostigmine reversal of neuromuscular blockade in laparoscopic surgery. Anaesthesia (2013) 1.07
Malakoplakia and immunosuppressive therapy. Reversal of clinical and leukocyte abnormalities after withdrawal of prednisone and azathioprine. Am J Pathol (1985) 1.06
Use of fractional myocardial flow reserve to assess the functional significance of intermediate coronary stenoses. Am J Cardiol (2000) 1.05
Detection of virtually all mutations-SSCP (DOVAM-S): a rapid method for mutation scanning with virtually 100% sensitivity. Biotechniques (1999) 1.05
Controlled study of the cytotoxic food test. JAMA (1975) 1.05
Sequence variation in the capsid protein genes of human papillomavirus type 16. J Gen Virol (1994) 1.05
Transformation of primary human fibroblast cells with human papillomavirus type 16 DNA and EJ-ras. Int J Cancer (1988) 1.05
Papilloma viruses and cervical tumours. Nature (1984) 1.04
Preoperative evaluation for diabetic renal transplantation: impact of clinical, laboratory, and echocardiographic parameters on patient and allograft survival. Am J Med (1992) 1.02
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat (2010) 1.02
Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation (1997) 1.02
Screening for asymptomatic coronary artery disease in diabetes. Diabetes Care (1999) 1.01
Predictive value of latent tuberculosis tests in Indian healthcare workers: a cohort study. Eur Respir J (2011) 1.00
Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet (1997) 1.00
The interaction between human papillomavirus type 16 E1 and E2 proteins is blocked by an antibody to the N-terminal region of E2. Eur J Biochem (1995) 1.00
Technetium-99m-tetrofosmin to assess myocardial blood flow: experimental validation in an intact canine model of ischemia. J Nucl Med (1994) 1.00
In-utero and neonatal exposure to secondhand smoke causes vascular dysfunction in newborn rats. J Am Coll Cardiol (1998) 0.98
Urgent coronary bypass surgery for failed percutaneous coronary intervention in the stent era: Is backup still necessary? Am Heart J (2001) 0.98
Epitope-mapped monoclonal antibodies against the HPV16E1--E4 protein. Virology (1992) 0.98
Congenital myopathies--a comprehensive update of recent advancements. Acta Neurol Scand (2009) 0.98
Physiological concentrations of estradiol attenuate endothelin 1-induced coronary vasoconstriction in vivo. Circulation (1997) 0.97
Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res (1991) 0.97
Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein. Int Immunol (1994) 0.97
The kinetics of [3H]-dsDNA/anti-DNA immune complex formation, binding by red blood cells, and release into serum: effect of DNA molecular weight and conditions of antibody excess. J Immunol (1984) 0.97
Factors responsible for delayed immunisation among children under 5 years of age. J Indian Med Assoc (2000) 0.97
Alternative splicing of human p53 transcripts. Oncogene Res (1987) 0.97
Expression of human papillomavirus type 6 and type 16 capsid proteins in bacteria and their antigenic characterization. J Gen Virol (1987) 0.97
The safety and efficacy of the StarClose Vascular Closure System: the ultrasound substudy of the CLIP study. Catheter Cardiovasc Interv (2006) 0.96
Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: correlation with high density lipoproteins. J Am Coll Cardiol (1996) 0.96
Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5. Mol Psychiatry (2004) 0.96
Interaction of the E6 protein of human papillomavirus with cellular proteins. Oncogene (1994) 0.96
Cytomegalovirus infection masquerading as an ulcerative colitis flare-up: case report and review of the literature. Yale J Biol Med (1997) 0.94
Papillary tumor of the pineal region--a recently described entity: a report of three cases and review of the literature. Clin Neuropathol (2009) 0.94
Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. J Gen Virol (1994) 0.94
Analysis of human papillomavirus sequences in cell lines recently derived from cervical cancers. Cancer Res (1988) 0.92
Tropomyosin lysine reactivities and relationship to coiled-coil structure. Biochemistry (1985) 0.92
A cAMP-regulated RNA-binding protein that interacts with phosphoenolpyruvate carboxykinase (GTP) mRNA. J Biol Chem (1993) 0.92